Introduction: A Milestone Achievement for Dr. Peter Zang
Peter Zang, MD, a second-year fellow at City of Hope, has reached a career-defining moment by being named the 2025 Cary Presant, MD Investigator Award winner. Presented by the Medical Oncology Association of Southern California (MOASC) and accompanied by a $25,000 research grant from AVEO Oncology, this honor reflects his relentless dedication. Dr. Zang calls it a “huge deal” after years of pursuing young investigator awards, and it positions him to advance cancer research with real patient impact. At City of Hope, a hub for innovative oncology, he’s ready to make waves with this prestigious recognition.
Dr. Zang’s Journey at City of Hope
Thriving as a second-year fellow, Dr. Zang credits City of Hope’s supportive environment for his growth. “I’ve loved this program so far and continue to love it,” he says, highlighting how the institution has shaped his path as a physician-researcher. The Cary Presant, MD Investigator Award, bestowed by MOASC, underscores his potential to lead transformative work in cancer care. With AVEO Oncology’s $25,000 grant, Dr. Zang is equipped to take his research to new heights within City of Hope’s cutting-edge framework.
Research Focus: Exploring ABBV-969 in Prostate Cancer
Dr. Zang’s award-winning project investigates ABBV-969, a novel agent targeting metastatic castrate-resistant prostate cancer (mCRPC). This challenging cancer type demands innovative solutions, and Dr. Zang is studying how the tumor microenvironment reacts to ABBV-969 therapy. Backed by the $25,000 grant from AVEO Oncology and MOASC’s recognition, he aims to uncover insights that could enhance treatment outcomes. His research promises to advance the fight against mCRPC, a priority in oncology.
Inspiration from Patients: A Driving Force
Dr. Zang’s work is deeply inspired by his patients. “They work so hard to fight their disease and often ask how treatments affect their cancer,” he shares. These questions propel his mission to improve therapies. “If we can answer that, we can make treatments even better,” he says, embodying a patient-centered approach. The Cary Presant, MD Investigator Award from MOASC amplifies his ability to address these concerns through research.
The Challenge of Current Cancer Therapies
Though cancer treatments have progressed, Dr. Zang notes a critical limitation: “Most of them, in fact, aren’t curative.” This gap drives his exploration of ABBV-969 and the tumor microenvironment. With MOASC’s award and AVEO Oncology’s $25,000 grant, he’s tackling the need to understand therapy mechanisms at a cellular level. His efforts aim to bridge the divide between current options and curative solutions for metastatic castrate-resistant prostate cancer.
The Power of the Cary Presant, MD Investigator Award
Awarded by MOASC and supported by a $25,000 grant from AVEO Oncology, the Cary Presant, MD Investigator Award empowers Dr. Zang to pursue his vision. “I’m really excited that I’ll have the opportunity with this grant to further explore that research,” he says. The funding and recognition will fuel in-depth studies and collaborations, enhancing his capacity to benefit patients. This accolade, rooted in MOASC’s mission to advance oncology, elevates Dr. Zang’s work significantly.
Mentorship at City of Hope: A Foundation for Success
Dr. Zang credits his success to City of Hope’s exceptional mentors: Dr. Tanya Dorf, a guide since medical school; Dr. Monty Pav, a source of life and career wisdom; and Dr. Ravi Salia, head of medical oncology. “I’ve been so blessed to work under their mentorship,” he says. Their support helped him secure the Cary Presant, MD Investigator Award from MOASC, showcasing the collaborative spirit that defines City of Hope.
Looking Ahead: Impacting Cancer Care
With MOASC’s Cary Presant, MD Investigator Award and AVEO Oncology’s $25,000 grant, Dr. Zang is set to advance his research and share its impact. “I can ultimately benefit the patients,” he emphasizes, focusing on real-world outcomes. His study of ABBV-969 could redefine prostate cancer treatment, offering hope to mCRPC patients. Dr. Zang invites readers to follow his progress as he leverages this support to shape oncology’s future.
Conclusion: A Bright Future for Dr. Zang and Cancer Research
Dr. Peter Zang’s recognition with the Cary Presant, MD Investigator Award from MOASC, paired with a $25,000 research grant from AVEO Oncology, celebrates his talent and commitment to oncology. At City of Hope, he’s harnessing this opportunity to explore ABBV-969 and metastatic castrate-resistant prostate cancer. Guided by stellar mentors and inspired by patients, Dr. Zang is on track to transform cancer care. Keep an eye on this rising star as he drives innovation forward!
Related Links: